This study explores long-term oncologic outcomes in men with lymph node invasion at radical prostatectomy and persistently detectable prostate-specific antigen (PSA) post-surgery.
Among 253 patients, 126 developed metastasis. The 5- and 10-year metastasis-free survival rates were 52% and 37%, respectively, while prostate cancer-specific survival rates were 89% and 67%.
Most patients underwent hormonal deprivation treatment, with only ten receiving postoperative radiotherapy.
The findings highlight the high risk of disease progression and reduced survival in these patients, suggesting that novel molecular imaging could enhance staging and inform more tailored therapeutic strategies.
